Jasper Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Jasper Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $28.69 million for the year ending 2025.

  • Jasper Therapeutics, Inc. showed a decrease of -59.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Jasper Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Jasper Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 2,265.9%.
  • Historical annual values: Fiscal year 2025: $28.69 million | Fiscal year 2024: $71.64 million | Fiscal year 2023: $86.89 million | Fiscal year 2022: $38.25 million | Fiscal year 2021: $84.70 million | Fiscal year 2020: $19.84 million | Fiscal year 2019: $1.21 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: